2011
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal Of Medicine 2011, 365: 1492-1501. PMID: 22010915, PMCID: PMC3233684, DOI: 10.1056/nejmoa1014181.Peer-Reviewed Original ResearchConceptsImmune reconstitution inflammatory syndromeT-cell countsEarly ART groupLater-ART groupInitiation of ARTAntiretroviral therapyTuberculosis treatmentIncidence rateCubic millimeterAdverse eventsRisk of IRISHuman immunodeficiency virus (HIV) infectionReconstitution inflammatory syndromeMedian viral loadImmunodeficiency virus infectionAIDS-free survivalRisk of AIDSHigher CD4Median CD4Inflammatory syndromeAmbulatory patientsImmunodeficiency syndromeViral loadContinuation phaseAntiretroviral drugs
2010
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2008
The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy on Quality of Life
Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy on Quality of Life. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 47: 185-193. PMID: 17971716, DOI: 10.1097/qai.0b013e31815acaa4.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDrug Administration ScheduleFemaleHIV InfectionsHumansMaleMiddle AgedQuality of LifeConceptsQuality of lifeEpisodic antiretroviral therapyAntiretroviral therapyDisease progressionQoL assessmentTherapy groupInferior QOLMedian CD4 lymphocyte countContinuous therapy groupExcellent general healthCD4 cell countCD4 lymphocyte countCells/mm3HIV disease progressionCurrent healthAntiretroviral Therapy studyTherapy armMean followContinuous therapyLymphocyte countAnalog scaleQOL outcomesGeneral healthQOL instrumentsQoL comparisonsA randomized comparison of two instruments for measuring self-reported antiretroviral adherence
Mannheimer S, Thackeray L, Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G, Aids F. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008, 20: 161-169. PMID: 18293124, DOI: 10.1080/09540120701534699.Peer-Reviewed Original ResearchConceptsSelf-reported adherenceImmunologic outcomesAntiretroviral adherenceStudy visitRecall instrumentSelf-reported antiretroviral adherenceCD4 cells/HIV resistance mutationsMultidrug-resistant HIVSelf-report instrumentVirologic failureAntiretroviral medicationsHIV diseaseMonth 12Randomized comparisonClinical trialsTreatment strategiesAdherence levelsResistance mutationsAdherenceCells/VisitsTrialsDaysMedian
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysiciansInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphineInteractions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increaseHIV Medication Adherence
Friedland GH. HIV Medication Adherence. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s3-s9. PMID: 17133202, DOI: 10.1097/01.qai.0000248333.44449.ea.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsBehavioral SciencesDrug Administration ScheduleHIV InfectionsHumansPatient CompliancePractice Patterns, Physicians'Research
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAtazanavir SulfateDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHIV Protease InhibitorsHumansMaleMethadoneMiddle AgedOligopeptidesOpioid-Related DisordersPyridinesConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
2002
Report on the XIV International AIDS Conference.
Abdool Karim SS, Currier J, del Rio C, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. Infectious Diseases 2002, 14: 77-85. PMID: 12236208.Peer-Reviewed Original Research